Evaluating Renal Artery Denervation Combined With Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone to Reduce Persistent Atrial Fibrillation
Led by University of Rochester · Updated on 2026-10-13
50
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether adding renal artery denervation RDN to pulmonary vein isolation PVI improves long-term control of persistent atrial fibrillation AF in patients with controlled or no hypertension. This pilot study builds on prior findings that RDN plus PVI reduced AF recurrence in patients with uncontrolled hypertension. The trial uses implantable loop recorders to closely monitor AF burden, aiming to compare the effectiveness of PVI alone versus PVI combined with RDN.
Participants will undergo catheter ablation of all pulmonary veins using cryoballoon energy. Those in the experimental group will receive additional radiofrequency ablation of the renal arteries to reduce cardiac sympathetic nerve activity. The study is randomized and single-blinded, with patients assigned to either PVI alone or PVI plus RDN. The interventions safety, blood pressure effects, nervous system modulation, and impact on quality of life will also be assessed.
During the year-long study, participants will have implantable loop recorders placed to continuously track AF episodes. Follow-up visits will measure blood pressure, autonomic function, quality of life, and any adverse effects. Researchers will evaluate AF burden at 12 months as the primary outcome, along with secondary outcomes including procedural complications, emergency visits, hospitalizations, and mortality. The total participation time spans 12 months post-procedure.
CONDITIONS
Brief Title
Renal Denervation + PVI vs PVI Alone for Persistent AF
Research Team
J
Jonathan Steinberg, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
PVI + RDN (trial investigational)
PVI alone (trial comparator)
Standard PVI (current guideline‑based care)
What it is
Combination of pulmonary vein isolation plus renal artery denervation (catheter‑based procedures)
Pulmonary vein isolation alone via catheter ablation
Pulmonary vein isolation alone is the established guideline‑recommended approach for persistent atrial fibrillation
Role in trial
Novel investigational combination arm
Control arm representing current procedural standard
Represents current real‑world guideline‑based treatment outside trial
Primary use
To assess whether adding renal denervation improves long‑term AF control when combined with PVI
To serve as comparator evaluating the effect of PVI alone
Used in current care to isolate pulmonary veins as treatment for persistent AF
How it is performed
Cryoballoon catheter ablation of pulmonary veins plus radiofrequency renal artery denervation
Cryoballoon catheter ablation of pulmonary veins only
Catheter ablation targeting pulmonary veins using standard energy modalities
Evidence status
Efficacy under investigation; benefit over PVI alone is not yet established
PVI alone has demonstrated effectiveness in reducing AF recurrence in persistent AF
PVI alone is the current backbone of rhythm control strategy according to clinical guidelines
Important limitations
Results are not yet available; small pilot trial limits definitive conclusions
Effectiveness may vary based on patient factors such as hypertension and AF chronicity
Does not address underlying contributors such as sympathetic overactivity in AF recurrence
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Age over 18 years
Symptomatic persistent atrial fibrillation lasting more than 7 days and up to 1 year
No history of high blood pressure or controlled hypertension with medication (SBP <140 mm Hg and DBP <85 mm Hg)
Accessible renal arteries confirmed by pre-procedure imaging
Willingness to undergo implantable loop recorder placement
Willingness to comply with follow-up and provide informed consent
You will not qualify if you...
Unable to undergo catheter ablation due to medical reasons (e.g., left atrial thrombus, contraindications to anticoagulation)
Prior left atrial ablation for atrial arrhythmia
Severe heart failure (NYHA class IV) or left ventricular ejection fraction below 25%
Paroxysmal or longstanding persistent atrial fibrillation lasting more than 1 year
Recent coronary revascularization or valve surgery within 3 months
Mechanical heart valve prosthesis
Renal artery anatomy unsuitable for treatment, including small arteries, significant abnormalities, prior interventions, or multiple main renal arteries
Life expectancy less than 1 year due to any medical condition
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 1 day
Participants undergo catheter ablation of pulmonary veins using cryoballoon energy. Those assigned to the experimental group receive additional renal artery denervation with radiofrequency energy.
1 procedure visit
Follow-up
Duration - 12 months
Participants have an implantable loop recorder placed to continuously monitor heart rhythm. Regular visits occur to assess blood pressure, autonomic nervous system function, quality of life, and any adverse events over 12 months.
Regular follow-up visits
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Using 320-Detector CT to Measure Heart Tissue Fibrosis in Adults with Atrial Fibrillation
Before Catheter Ablation Treatment
Long-Term Safety and Effectiveness Evaluation of the VARIPULSE Catheter System in Symptomatic Paroxysmal Atrial Fibrillation Management
Evaluating Safety and Effectiveness of Dual Energy THERMOCOOL SMARTTOUCH SF Catheter With TRUPULSE Generator in Persistent Atrial Fibrillation
Evaluating Varipulse Catheter Ablation Using Different Anesthesia Types in Adults With Paroxysmal Atrial Fibrillation
Safety and Effectiveness of the VARIPULSE Catheter System for Treating Persistent Atrial Fibrillation
Using Pulmonary Vein, Superior Vena Cava, and Posterior Wall Isolation
Including Left Atrial Appendage Occlusion Procedures
Randomized Trial Comparing VARIPULSE and FARAWAVE Pulsed Field Ablation Catheters in Treating Persistent Atrial Fibrillation
Randomized, Double-Blind Study Evaluating Oral PKN605 Compared to Placebo in Adults with Atrial Fibrillation to Assess Efficacy, Safety, and Pharmacokinetics
Evaluating BAY 3670549 Compared to Placebo for Treating Atrial Fibrillation with Electrical Cardioversion in Adults
Village Doctor-led Telehealth Care vs Usual Care for Older Adults with Atrial Fibrillation and Heart Failure in Rural China The MIRACLE AF-HF Trial
Telehealth-Supported Village Doctor-Led Trial for Preventing Heart Failure in Older Rural Patients with Atrial Fibrillation
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial.
Jonathan S Steinberg, Vitaliy Shabanov, Dmitry Ponomarev...